High Plasma Pentraxin 3 Levels in Diabetic Polyneuropathy Patients with Nociceptive Pain

Salcini C., Atasever-Arslan B., Sunter G. , Gur H., Isik F. B. , Saylan C. C. , ...Daha Fazla

TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, cilt.239, sa.1, ss.73-79, 2016 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 239 Konu: 1
  • Basım Tarihi: 2016
  • Doi Numarası: 10.1620/tjem.239.73
  • Sayfa Sayıları: ss.73-79


Diabetic polyneuropathy is the most common neurologic complication of diabetes mellitus. Underlying mechanisms of diabetic polyneuropathy are related to various metabolic and inflammatory pathways. Pentraxin 3 (PTX3) is an acute phase protein that is produced locally at the inflammatory sites by several cell types. Thioredoxin binding protein 2 (TBP2) is a thioredoxin regulator involved in intracellular energy pathways and cell growth. We measured the plasma levels of PTX3 and TBP2 in type 2 diabetic patients (n = 27) with pain complaints and compared their levels with those of healthy age-and sex-matched subjects (n = 24). Moreover, the diabetic patients were divided into two groups using the Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale: patients with nociceptive pain that is caused by tissue damage and patients with neuropathic pain that is caused by nerve damage. Patients with LANSS scores of < 12 were considered to have nocicceptive pain (n = 15), while patients with LANSS scores of >= 12 were considered to have neuropathic pain (n = 12). We found that PTX3 levels were significantly higher in diabetic patients compared to controls (p = 0.03), but there was no significant difference in the TBP2 levels. Importantly, patients with nociceptive pain had significantly higher PTX3 levels compared to patients with neuropathic pain (p < 0.05). Thus, plasma PTX3 levels can be helpful for discrimination of nociceptive pain from neuropathic pain in diabetic patients. We propose that PTX3 may contribute to the onset of nociceptive pain.